Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's DiseaseStephen Salloway, H. Robert Brashear, Murray A. Raskind et al.|New England Journal of Medicine|2014Cited by 2k
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable WorkgroupReisa A. Sperling, Rachel Schindler, Clifford R. Jack et al.|Alzheimer s & Dementia|2011Cited by 830
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer diseaseStephen Salloway, Michael Grundman, Reisa A. Sperling et al.|Neurology|2009Cited by 739
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysisReisa A. Sperling, Michael Grundman, Stephen Salloway et al.|The Lancet Neurology|2012Cited by 510
Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive declineP. Murali Doraiswamy, Reisa A. Sperling, Robert E. Coleman et al.|Neurology|2012Cited by 228